Clinical Trials · NCT01070758

Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy

Phase
Phase 4
Recruitment status
Completed
Sponsor
Sheba Medical Center
Enrollment
3
Start date
Feb 2010
Locations
1 site, Israel
Primary endpoint
Euglycemia as recorded by Continuous Glucose Monitoring System (CGMS)
View Octreotide compound reference